Prevalence and incidence of acute and chronic comorbidity in patients with squamous cell carcinoma of the head and neck

S. H. Landis; I. A. El-Hariry; M. P. van Herk-Sukel; P. van den Haak; M. L. Janssen-Heijnen; F. J. Penning-van Beest; R. M. Herings

doi:https://doi.org/10.1002/hed.21720

Prevalence and incidence of acute and chronic comorbidity in patients with squamous cell carcinoma of the head and neck

S. H. Landis, I. A. El-Hariry, M. P. van Herk-Sukel, P. van den Haak, M. L. Janssen-Heijnen, F. J. Penning-van Beest, R. M. Herings

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: Limited data exist on the burden of comorbidity among patients with squamous cell head and neck cancer (SCCHN) before and during cancer treatment. METHODS: The precancer prevalence and incidence rates of 8 comorbid conditions were estimated among a population-based cohort of 1499 patients with SCCHN in the Netherlands. Patients with cancer, treatments, and comorbidities were identified in the PHARMO Record Linkage System (RLS) using hospital admissions and/or dispensing codes. Prevalence proportions and incidence rates were also compared against a matched cancer-free population. RESULTS: Cardiovascular (41%) and respiratory diseases (12%) were the most prevalent comorbidities. Incidence rates of most comorbidities were highest the first 6 months after cancer diagnosis and decreased over time. Patients receiving chemotherapy-based treatment had significantly higher incidence rates of anemia and other malignant diseases. CONCLUSIONS: High rates of acute and chronic comorbidity were observed; knowledge of comorbidity burden aids in establishing a benefit-risk profile for investigational SCCHN therapies.

Original language	English
Pages (from-to)	238-244
Number of pages	7
Journal	Head and Neck
Volume	34
Issue number	2
DOIs	https://doi.org/10.1002/hed.21720
Publication status	Published - 2012

Keywords

Aged Carcinoma, Squamous Cell/*epidemiology/psychology Cardiovascular Diseases/epidemiology Comorbidity Depression/epidemiology Diabetes Mellitus/epidemiology Female Head and Neck Neoplasms/*epidemiology/psychology Humans Incidence Male Middle Aged Precancerous Conditions/epidemiology Prevalence Respiratory Tract Diseases/epidemiology Squamous Cell Carcinoma of Head and Neck

Access to Document

https://doi.org/10.1002/hed.21720

https://www.ncbi.nlm.nih.gov/pubmed/21608062

Cite this

@article{a516218fe146412698831a686bf9432d,

title = "Prevalence and incidence of acute and chronic comorbidity in patients with squamous cell carcinoma of the head and neck",

abstract = "BACKGROUND: Limited data exist on the burden of comorbidity among patients with squamous cell head and neck cancer (SCCHN) before and during cancer treatment. METHODS: The precancer prevalence and incidence rates of 8 comorbid conditions were estimated among a population-based cohort of 1499 patients with SCCHN in the Netherlands. Patients with cancer, treatments, and comorbidities were identified in the PHARMO Record Linkage System (RLS) using hospital admissions and/or dispensing codes. Prevalence proportions and incidence rates were also compared against a matched cancer-free population. RESULTS: Cardiovascular (41%) and respiratory diseases (12%) were the most prevalent comorbidities. Incidence rates of most comorbidities were highest the first 6 months after cancer diagnosis and decreased over time. Patients receiving chemotherapy-based treatment had significantly higher incidence rates of anemia and other malignant diseases. CONCLUSIONS: High rates of acute and chronic comorbidity were observed; knowledge of comorbidity burden aids in establishing a benefit-risk profile for investigational SCCHN therapies.",

keywords = "Aged Carcinoma, Squamous Cell/*epidemiology/psychology Cardiovascular Diseases/epidemiology Comorbidity Depression/epidemiology Diabetes Mellitus/epidemiology Female Head and Neck Neoplasms/*epidemiology/psychology Humans Incidence Male Middle Aged Precancerous Conditions/epidemiology Prevalence Respiratory Tract Diseases/epidemiology Squamous Cell Carcinoma of Head and Neck",

author = "Landis, {S. H.} and El-Hariry, {I. A.} and {van Herk-Sukel}, {M. P.} and {van den Haak}, P. and Janssen-Heijnen, {M. L.} and {Penning-van Beest}, {F. J.} and Herings, {R. M.}",

note = "Landis, Sarah H El-Hariry, Iman A van Herk-Sukel, Myrthe P P van den Haak, Pieter Janssen-Heijnen, Maryska L G Penning-van Beest, Fernie J A Herings, Ron M C eng Research Support, Non-U.S. Gov't Head Neck. 2012 Feb;34(2):238-44. doi: 10.1002/hed.21720. Epub 2011 May 23.",

year = "2012",

doi = "https://doi.org/10.1002/hed.21720",

language = "English",

volume = "34",

pages = "238--244",

journal = "Head and Neck",

issn = "1097-0347",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - Prevalence and incidence of acute and chronic comorbidity in patients with squamous cell carcinoma of the head and neck

AU - Landis, S. H.

AU - El-Hariry, I. A.

AU - van Herk-Sukel, M. P.

AU - van den Haak, P.

AU - Janssen-Heijnen, M. L.

AU - Penning-van Beest, F. J.

AU - Herings, R. M.

N1 - Landis, Sarah H El-Hariry, Iman A van Herk-Sukel, Myrthe P P van den Haak, Pieter Janssen-Heijnen, Maryska L G Penning-van Beest, Fernie J A Herings, Ron M C eng Research Support, Non-U.S. Gov't Head Neck. 2012 Feb;34(2):238-44. doi: 10.1002/hed.21720. Epub 2011 May 23.

PY - 2012

Y1 - 2012

N2 - BACKGROUND: Limited data exist on the burden of comorbidity among patients with squamous cell head and neck cancer (SCCHN) before and during cancer treatment. METHODS: The precancer prevalence and incidence rates of 8 comorbid conditions were estimated among a population-based cohort of 1499 patients with SCCHN in the Netherlands. Patients with cancer, treatments, and comorbidities were identified in the PHARMO Record Linkage System (RLS) using hospital admissions and/or dispensing codes. Prevalence proportions and incidence rates were also compared against a matched cancer-free population. RESULTS: Cardiovascular (41%) and respiratory diseases (12%) were the most prevalent comorbidities. Incidence rates of most comorbidities were highest the first 6 months after cancer diagnosis and decreased over time. Patients receiving chemotherapy-based treatment had significantly higher incidence rates of anemia and other malignant diseases. CONCLUSIONS: High rates of acute and chronic comorbidity were observed; knowledge of comorbidity burden aids in establishing a benefit-risk profile for investigational SCCHN therapies.

AB - BACKGROUND: Limited data exist on the burden of comorbidity among patients with squamous cell head and neck cancer (SCCHN) before and during cancer treatment. METHODS: The precancer prevalence and incidence rates of 8 comorbid conditions were estimated among a population-based cohort of 1499 patients with SCCHN in the Netherlands. Patients with cancer, treatments, and comorbidities were identified in the PHARMO Record Linkage System (RLS) using hospital admissions and/or dispensing codes. Prevalence proportions and incidence rates were also compared against a matched cancer-free population. RESULTS: Cardiovascular (41%) and respiratory diseases (12%) were the most prevalent comorbidities. Incidence rates of most comorbidities were highest the first 6 months after cancer diagnosis and decreased over time. Patients receiving chemotherapy-based treatment had significantly higher incidence rates of anemia and other malignant diseases. CONCLUSIONS: High rates of acute and chronic comorbidity were observed; knowledge of comorbidity burden aids in establishing a benefit-risk profile for investigational SCCHN therapies.

KW - Aged Carcinoma, Squamous Cell/epidemiology/psychology Cardiovascular Diseases/epidemiology Comorbidity Depression/epidemiology Diabetes Mellitus/epidemiology Female Head and Neck Neoplasms/epidemiology/psychology Humans Incidence Male Middle Aged Precance

U2 - https://doi.org/10.1002/hed.21720

DO - https://doi.org/10.1002/hed.21720

M3 - Article

SN - 1097-0347

VL - 34

SP - 238

EP - 244

JO - Head and Neck

JF - Head and Neck

IS - 2

ER -